LAST MINUTE GESCHENK mit Herz und Verstand: Der FLEXINVEST JUNIOR-SPARPLAN. Hier KOSTENLOS abschließen & bis zu 75 € Amazon.de* Gutscheine erhalten!

Roche Aktie

NeuKaufen Kaufen Verkaufen Verkaufen

263,10 EUR -8,90 EUR -3,27 %

19.12.2024

L&S

247,70 CHF -8,30 CHF -3,24 %

19.12.2024

BRX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.218,19 Mrd. EUR

KGV16,99Div. Rendite3,93%

WKN855167

ISINCH0012032048

SymbolRHHVF

Roche Aktien News

Sortieren:Datum Meistgelesen

19.12.24Roche Holding AGRoche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

19.12.24GlobeNewswireRoche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

18.12.24GlobeNewswireRoche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

WerbungRoche-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

18.12.24Roche Holding AGRoche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

13.12.24GlobeNewswireRoche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

13.12.24Roche Holding AGRoche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

13.12.24GlobeNewswireRoche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

10.12.24Roche Holding AGNew and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

10.12.24GlobeNewswireNew and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

09.12.24GlobeNewswireRoche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

09.12.24Roche Holding AGRoche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

08.12.24GlobeNewswireFive-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

08.12.24Roche Holding AGFive-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

05.12.24Roche Holding AGFDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

05.12.24GlobeNewswireFDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

26.11.24GlobeNewswireRoche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

26.11.24Roche Holding AGRoche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

26.11.24Roche Holding AGRoche reports update on Phase III SKYSCRAPER-01 study results

26.11.24GlobeNewswireRoche reports update on Phase III SKYSCRAPER-01 study results

25.11.24PR NewswireRoche receives FDA approval for first companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with ZIIHERA

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.